Drug Trial Radar · NCT05844787
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 11, 2022
Primary completion
Feb 23, 2023
Study completion Feb 23, 2023
Sponsor
- Lead sponsor
- Mthera Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Amarex Clinical Research
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers. The safety and overall tolerability of MT101-5 will be evaluated based on: * Incidence of Dose Limiting Toxicities (DLTs) * Incidence of Treatment-Emergent Adverse Events (TEAEs). * Incidence of withdrawals due to Adverse Events (AEs). * Change/shifts in laboratory values. Change in vital signs. * Change in Electrocardiogram (ECG) parameters. * Changes in physical examination findings
Conditions
- Parkinson's Disease
Interventions
MT101-5Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Day 1 through 7 days after the last study drug administration
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through 7 days after the last study drug administration
- Incidence of withdrawals due to Adverse Events (AEs)Time frame: Day 1 through 7 days after the last study drug administration
- Change in complete blood count testTime frame: Change from baseline to day 7 after the first study drug administration
- Change in comprehensive metabolic panel testTime frame: Change from baseline to day 7 after the first study drug administration
- Change in urinalysis testTime frame: Change from baseline to day 7 after the first study drug administration
- Change in pregnancy testTime frame: Change from baseline to day 7 after the first study drug administration
- Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from pre-dose to 96 hours after last study drug administration
- Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from pre-dose to day 7 after the last study drug administration
- Change of pulseTime frame: Change from pre-dose to 96 hours after last study drug administration
- Change of pulseTime frame: Change from pre-dose to day 7 after the last study drug administration
- Change of temperatureTime frame: Change from pre-dose to 96 hours after last study drug administration
- Change of temperatureTime frame: Change from pre-dose to day 7 after the last study drug administration
- Change of respiratory rateTime frame: Change from pre-dose to 96 hours after last study drug administration
- Change of respiratory rateTime frame: Change from pre-dose to day 7 after the last study drug administration
- ECG ventricular rate (beats per minute)Time frame: At pre-dose
- ECG ventricular rate (beats per minute)Time frame: 96 hours after study drug administration
- ECG ventricular rate (beats per minute)Time frame: On day 7 after the last study drug administration
- PR interval (msec)Time frame: At pre-dose
- PR interval (msec)Time frame: 96 hours after study drug administration
- PR interval (msec)Time frame: On day 7 after the last study drug administration
- QRS interval (msec)Time frame: At pre-dose
- QRS interval (msec)Time frame: 96 hours after study drug administration
- QRS interval (msec)Time frame: On day 7 after the last study drug administration
- QT interval (msec)Time frame: At pre-dose
- QT interval (msec)Time frame: 96 hours after study drug administration
- QT interval (msec)Time frame: On day 7 after the last study drug administration
- QTc interval (msec)Time frame: At pre-dose
- QTc interval (msec)Time frame: 96 hours after study drug administration
- QTc interval (msec)Time frame: On day 7 after the last study drug administration
- Maximum observed plasma drug concentration (Cmax)Time frame: 0-96 hours
- Apparent terminal elimination half-life (t1/2)Time frame: 0-96 hours
- Time to maximum observed plasma drug concentration (Tmax)Time frame: 0-96 hours
- Area under the plasma drug concentration-time curve (AUC)Time frame: 0-96 hours
- Percentage of AUC0-∞ extrapolated from Tlast to infinity (AUCext)Time frame: 0-96 hours
- Apparent plasma clearance (CL/F)Time frame: 0-96 hours
- Apparent Volume of distribution (Vz/F)Time frame: 0-96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Frontage Clinical Services, 1nc.
Secaucus, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.